Dermatology experts detail how JAK inhibitors reshape vitiligo care, weighing topical vs oral options, real-world adherence hurdles, and payer barriers to access.
The JAK Inhibitor Shift in Vitiligo: A Critical Review of Clinical Data and Economic Realities
Advertisement
Advertisement
Trending on AJMC
1
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
2
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
3
Multi-Hit TP53 Linked to Shorter Survival in Chronic-Phase MPN Cohorts
4
Navigating GLP-1 Access & Prior Authorizations: Amanda Velazquez, MD
5